Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;65(14):46.
doi: 10.1167/iovs.65.14.46.

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

Kim Lien Huber  1 , Heiko Stino  1 , Irene Steiner  2 , Philipp Fuchs  1 , Felix Goldbach  1 , Julia Mai  1 , Bianca S Gerendas  1 , Katharina Kriechbaum  1 , Ursula Schmidt-Erfurth  1 , Andreas Pollreisz  1
Affiliations

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

Kim Lien Huber et al. Invest Ophthalmol Vis Sci. .

Abstract

Purpose: To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting.

Methods: Retrospective, interventional consecutive case series. Patients with DME were switched from aflibercept to faricimab and categorized based on central subfield thickness (CST) 4 weeks after last aflibercept injection into responding DME (rDME, CST reduction >20% or CST ≤ 250 µm) and nonresponding DME (nrDME, CST unchanged or increased). Patients received a loading dose of two monthly faricimab injections followed by a treat-and-extend regimen. Differences in response between rDME and nrDME were analyzed based on injection interval, change in CST, and visual acuity (VA) 12 weeks postswitch.

Results: Fifty-two eyes of 40 patients met inclusion criteria (rDME: n = 26, nrDME: n = 26). Baseline and week 12: VA (logMAR) rDME 0.29 ± 0.23 and 0.22 ± 0.28, nrDME 0.42 ± 0.32 and 0.36 ± 0.29; CST (µm) rDME 370 ± 99 and 288 ± 80, nrDME 384 ± 85 and 380 ± 129. After 12 weeks, 54% rDME and 25% nrDME eyes showed a CST decrease of >20% or CST ≤ 250 µm. Forty-six percent rDME and 50% nrDME eyes had a ±20% CST change, 25% of nrDME eyes had a >20% CST increase, and 73% of rDME eyes and 47% of nrDME eyes reached an extended interval of 8 weeks or longer after 12 weeks.

Conclusions: Most DME eyes previously responding or not responding to aflibercept experienced a reduction or stabilization of DME after 12 weeks of faricimab treatment. rDME showed a better anatomic response, and treatment intervals could be extended earlier and longer than nrDME.

PubMed Disclaimer

Conflict of interest statement

Disclosure: K.L. Huber, None; H. Stino, None; I. Steiner, None; P. Fuchs, None; F. Goldbach, None; J. Mai, Apellis (C), Boehringer Ingelheim (C), Roche (C); B.S. Gerendas, Roche (C), Zeiss (C), Abbvie (C), Bayer (C); K. Kriechbaum, None; U. Schmidt-Erfurth, Apellis (C, F), AbbVie (C, F), Alcon (F), Bayer (C), Medscape (C), Allergan (C), Roche (C), Boehringer (C), Aviceda (C), Annexon (C), Topcon (C), Alkeus (C), Genentech (C), Kodiak(C), Novartis(C), RetInSight (C), Apellis Pharmaceuticals (C); A. Pollreisz, Allergan (C), Bayer (C), Roche (C), Oertli Instruments (C)

Figures

Figure 1.
Figure 1.
Comparison of CST and visual acuity between responding DME and nonresponding DME. The boxplots illustrate the distribution across baseline, week 4, week 8, and week 12 with outliers indicated by dots. The mean value is indicated by a cross. In the bottom of the graph, the number of eyes (n) per group is shown. The P values derived from the mixed models with the difference to baseline as the dependent variable are shown above the graph. Significant P values are bold.
Figure 2.
Figure 2.
Pie charts of faricimab treatment response per week, DME responder group, and in total. Percentages of eyes with CST reduction >20% or CST<250 µm, CST ±20%, or CST increase >20% are color-coded and specified.
Figure 3.
Figure 3.
Barplot of faricimab treatment intervals (in weeks) among responding DME (n = 26 eyes), nonresponding DME (n = 26 eyes), and in total (n = 52 eyes). stop, faricimab stop.
See this image and copyright information in PMC

References

    1. Jampol LM, Glassman AR, Sun J.. Evaluation and care of patients with diabetic retinopathy. N Engl J Med . 2020; 382(17): 1629–1637. - PubMed
    1. Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A.. Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J . 2018; 42(5): 364–376. - PMC - PubMed
    1. Nguyen QD, Brown DM, Marcus DM, et al. .. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology . 2012; 119(4): 789–801. - PubMed
    1. Heier JS, Korobelnik JF, Brown DM, et al. .. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology . 2016; 123(11): 2376–2385. - PubMed
    1. Wells JA, Glassman AR, Ayala AR, et al. .. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology . 2016; 123(6): 1351–1359. - PMC - PubMed

MeSH terms

Substances